Stories from people navigating pediatrics — diagnosis, treatment, caregiving, and the ordinary days in between.
2 stories
Clinical Briefs
WHO recommends hydroxyurea for all children and adolescents with sickle cell anemia from 9 months to 19 years, shifting care toward early treatment regardless of symptom history.
Rayan Salih · September 2, 2026 · 7 min
Endocrinology & Metabolism
The FDA expanded teplizumab to patients ages 8–17 with stage 3 type 1 diabetes diagnosed within six weeks, based on evidence that it slows loss of insulin-producing function.
Rayan Salih · 7 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.